Sai Life Sciences Limited sustains growth momentum in Q2FY26

Revenue up by 36%; EBITDA up by 43%; Net Profit up by 100%

Hyderabad, November 06, 2025: Sai Life Sciences Limited (BSE: 544306 I NSE: SAILIFE), one of India’s fastest growing Contract Research, Development and Manufacturing Organizations (CRDMO) announced its financial results for the second quarter and half year ended September 2025.

Financial Performance:

Particulars (₹ crores)	Q2FY26	Q2FY25	YoY%	H1FY26	H1FY25	YoY%
Revenue from Operations	537	396	36%	1034	675	53%
EBITDA	156	109	43%	281	140	101%
EBITDA Margin%	29%	28%	-	27%	21%	-
PBT	112	55	104%	193	37	422%
PAT	84	42	100%	144	28	414%
PAT Margin%	16%	11%	-	14%	4%	-

Q2FY26 Highlights

• Revenue from Operations was ₹537 Cr for Q2FY26 compared to ₹396 Cr in Q2FY25, an increase of 36% driven by strong growth both in CRO and CDMO services
• EBITDA stood at ₹156 Cr. for Q2FY26 compared to ₹109 Cr in Q2FY25, an increase of 43%
• PAT stood at ₹84 Cr. for Q2FY26 compared to ₹42 Cr in Q2FY25, an increase of 100%

H1FY26 Highlights

• Revenue from Operations was ₹1034 Cr for H1FY26 compared to ₹675 Cr in H1FY25, an increase of 53%
• EBITDA stood at ₹281 Cr for H1FY26 compared to ₹140 Cr in H1FY25, an increase of 101%
• PAT stood at ₹144 Cr. for H1FY26 compared to ₹28 Cr in H1FY25, an increase of 414%

Business Highlights

• Deepened capabilities in new technologies and modalities
  • “Following-the-molecule” in peptides, the company is complementing existing discovery capability with development and scale-up capability
  • Successfully completed photo-flow chemistry scale-up at plant scale for a large pharma client
  • Completed bioconjugation at the discovery stage for a large pharma client; building OEB-6 labs for Discovery and CMC to strengthen ADC capabilities
  • Validating a phosphoramidite process for a commercial oligonucleotide molecule
• Successfully underwent 35 customer and 3 regulatory audits across manufacturing and R&D units in the past 12 months, with zero data integrity deviations and zero critical observations
• Completed phase 2 expansion of Vivarium, Hyderabad R&D Centre - added 12,000 sq. ft. (total 27,000 sq. ft.) with expanded preclinical and assay capabilities
• Partnered with Agility Life Sciences (UK) and Centrix Pharma (UK) to provide end-to-end CMC services from API development to drug product manufacturing and first-in-human trials
• Near-term GHG reduction targets were validated by SBTi reinforcing climate-aligned growth
• Signed UN Women’s Empowerment Principles (WEPs) - strengthens focus on gender equality and inclusive workplace practices

Commenting on the performance during the quarter, Mr. Krishna Kanumuri, Managing Director and CEO, Sai Life Sciences Limited, said, “We are pleased to report another strong quarter, supported by healthy demand across our discovery, development, and manufacturing services. The performance was driven by consistent execution, growing client relationships, and continued traction in late-stage and commercial programs.
As the industry evolves toward more complex and diversified science, we continue to invest in new modalities, advanced technologies, and capacity expansion to strengthen our long-term competitiveness. These investments are enabling us to address a broader range of client needs, enhance efficiency across the value chain, and build deeper scientific capabilities for the future.
Looking ahead, our priorities remain centered on scaling responsibly, advancing technology-led innovation, and deepening client collaborations. With a strong foundation, expanding infrastructure, and scientific excellence at the core of our strategy, Sai Life Sciences is well positioned to deliver sustainable growth and long-term value."

Mr. Siva Chittor, Director and Chief Financial Officer, Sai Life Sciences Limited added, “We sustained our positive momentum this quarter, maintaining growth across our business and keeping Sai Life Sciences firmly on track toward its long-term aspirations. Total revenue for Q2FY26 stood at ₹537 Cr, up 36% year-on-year, driven by healthy performance across both the CRO and CDMO services. EBITDA for the quarter was ₹156 Cr, with margins at 29%, supported by improved operating leverage, better utilization and continued cost discipline. We incurred capex of ₹248 Cr during H1, primarily directed toward expanding our R&D capacity, and advancing our offerings in new modalities and technologies. These investments are aligned with our strategy to enhance scientific depth and build scalable capacity to support future growth.
We remain focused on maintaining financial discipline, driving margin improvement, and deploying capital effectively to sustain long-term, profitable growth.”

About Sai Life Sciences Limited (BSE: 544306 I NSE: SAILIFE)
Sai Life Sciences is one of India’s fastest growing Contract Research, Development, and Manufacturing Organizations (CRDMO) that partners with innovator pharmaceutical and biotech companies to accelerate the discovery, development, and commercialization of new medicines. Headquartered in Hyderabad, India, with a strong global presence, the company offers integrated solutions spanning medicinal chemistry, process development, clinical and commercial manufacturing, and advanced technology platforms. Sai Life Sciences is committed to delivering high-quality, cost-effective, and scalable solutions while upholding the highest standards of safety, compliance, and integrity. With a focus on innovation and operational excellence, the company continues to strengthen its capabilities to support emerging therapeutic modalities and meet the evolving needs of the life sciences industry.

For more information, please visit www.sailife.com

For further details, please feel free to contact: Investorrelation@sailife.com

Disclaimer:
This press release may include statements of future expectations and other forward-looking statements based on management's current expectations and beliefs concerning future developments and their potential effects on the Company. These forward-looking statements involve known or unknown risks and uncertainties that could cause actual results, performance, or events to differ materially from those expressed or implied in such statements. Forward-looking statements are provided to allow potential investors the opportunity to understand management’s beliefs and opinions in respect of the future so that they may use such beliefs and opinions as one factor in evaluating an investment. These statements are not guarantees of future performance and undue reliance should not be placed on them. Important factors that could cause actual results to differ materially from our expectations include, amongst other: general economic and business conditions in India, our ability to successfully implement our strategy, our research and development efforts, our growth and expansion plans and technological changes, change in laws and regulations that apply to pharmaceuticals, increasing competition in and changes in political conditions in India. Neither Sai Life, nor our directors, assume any obligation to update any forward-looking statement contained in this release. The Company undertakes no obligation to update forward-looking statements if circumstances or management’s estimates or opinions should change except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking statements.